{"prompt": "['Page 4 of 74', 'Protocol 036 (Nishijima, Kuppermann)', 'THIS PAGE IS INTENTIONALLY BLANK.', 'TIC-TOC Trial Protocol Version 2.03', 'Protocol Version Date: October 24, 2018', 'The EMSC Pediatric Emergency Care Applied Research Network']['Protocol 036 (Nishijima, Kuppermann)', 'Page 5 of 74', 'Contents', '1 Study Summary', '9', '1.1 Study Objectives', '9', '1.2 Outcome Measures', '9', '1.3 Subject Eligibility, Accrual and Study Duration', '11', '1.3.1', 'Inclusion Criteria', '11', '1.3.2', 'Exclusion Criteria', '13', '2 Rationale and Background', '15', '2.1 Traumatic coagulopathy and hyperfibrinolysis increases morbidity and', 'mortality after pediatric trauma', '15', '2.2 Targeting fibrinolysis may attenuate post-traumatic hemorrhage and de-', 'crease blood product transfusion requirements', '16', '2.3 TXA has not been appropriately studied in children with hemorrhagic', 'injuries', '17', '3 Study Design and Data Collection', '17', '3.1 Study Design Overview', '17', '3.2 Participant Screening and Consent', '18', '3.2.1 Missed Eligible Subjects', '18', '3.3', 'Baseline Data Collection', '18', '3.3.1 Biomarker testing', '19', '3.4', 'Data Collection During Hospitalization', '21', '3.4.1', 'TXA levels', '22', '3.4.2 GCS score assessment and pupillary examination', '22', '3.4.3', 'Blood product transfusion volume', '22', '3.4.4', 'Hospital discharge information', '22', '3.5', 'Follow Up Data Collection', '24', '3.5.1 Pediatric Quality of Life (PedsQL), Pediatric GOS-E, and digit', 'span evaluations', '24', '3.6 General Management Principles', '24', '4 Study Procedures', '24', '4.1 Randomization (Enrollment)', '24', '4.2 Study Drug Administration', '26', '4.2.1', 'Rationale for Study Doses', '26', '4.2.2', 'Manufacturing and Distribution of the Study Drug', '28', '4.2.3', 'Study Drug Administration', '29', 'TIC-TOC Trial Protocol Version 2.03', 'Protocol Version Date: October 24, 2018', 'The EMSC Pediatric Emergency Care Applied Research Network']['Page 6 of 74', 'Protocol 036 (Nishijima, Kuppermann)', '4.2.4 Discontinuation of Study Drug', '30', '4.3 Blinding and Unblinding', '30', '5 Data Analysis', '34', '5.1 Outcomes', '34', '5.1.1', 'Blood Transfusion', '35', '5.1.2', 'Intracranial Hemorrhage Progression at 24 hours (plus or minus 6', 'hours)', '35', '5.1.3', 'PedsQL', '36', '5.1.4', 'Glasgow Outcome Score Extended (GOS-E) Peds', '36', '5.1.5', 'Digit Span Recall Test (working memory)', '37', '5.1.6', 'Biomarkers', '37', '5.1.7', 'Safety Outcomes', '37', '5.2 Randomization and Stratification', '38', '6 Data Management', '39', '6.1 Clinical Site Data Management', '39', '6.2 Electronic Data Capture System', '39', '6.3 Study Monitoring', '39', '6.3.1', 'Site Monitoring Plan', '39', '6.3.2', 'Clinical Site Monitoring', '40', '6.3.3', 'Remote Monitoring', '40', '6.3.4', 'Pharmacy Monitoring', '40', '6.4', 'Data Coordinating Center', '40', '6.4.1', 'Data Center Description', '40', '6.4.2', 'Security and Confidentiality', '42', '6.5 Record Access', '43', '7', 'Protection of Human Subjects', '43', '7.1 Institutional Review Board (IRB) Approval', '43', '7.1.1 Reporting of IRB Actions', '44', '7.2 Informed Consent', '44', '7.3', 'Exception from Informed Consent (EFIC)', '46', '7.4 Waiver of Informed Consent', '51', '7.5', 'Potential Risks', '52', '7.6', 'Protections Against Potential Risks', '54', '7.7', 'Potential Benefits', '55', '7.8 Withdrawal from Study', '55', 'TIC-TOC Trial Protocol Version 2.03', 'Protocol Version Date: October 24, 2018', 'The EMSC Pediatric Emergency Care Applied Research Network']\n\n###\n\n", "completion": "END"}